2024
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.
Tumati S, Herrmann N, Perin J, Rosenberg P, Lerner A, Mintzer J, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Shade D, Lanctôt K. Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2. International Psychogeriatrics 2024, 1-13. PMID: 39297292, DOI: 10.1017/s1041610224000711.Peer-Reviewed Original ResearchDementia Apathy Interview and RatingMinimal clinically important differenceDistribution-based analysisMeasure clinically relevant changesClinically important differenceClinically significant apathyAnchor-based analysesDementia careGlobal Impression of ChangeImpression of ChangeLinear mixed modelsAlzheimer's diseaseClinically relevant changesMMSE scoreImportant differenceApathy symptomsApathy ScaleControlled trialsSignificant apathyAnchor measuresDementiaStudy visitsApathy severityMethylphenidate trialSymptom severity
2023
P105: Measuring clinically relevant change in apathy symptoms in ADMET 2
Tuma S, Herrmann N, Perin J, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, CraG S, Levey A, Shade D, Mintzer J, Lanctôt K. P105: Measuring clinically relevant change in apathy symptoms in ADMET 2. International Psychogeriatrics 2023, 35: 126-127. DOI: 10.1017/s1041610223002569.Peer-Reviewed Original ResearchImpression of ChangeChange scoresMeasure clinically relevant changesNPI apathy scoreEffect sizeClinical impression of changeMinimal clinically significant improvementClinical Global Impression of ChangeSpearman correlationClinical Global ImpressionClinically significant improvementSix-month visitGlobal Impression of ChangePsychosocial interventionsClinically relevant changesApathy symptomsAssessment ScaleAssessment Change ScoreMann-Whitney U testComplete dataWorsened groupParticipantsApathyNo changeTreatment trialsCorrelation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial
Lanctôt K, Sankhe K, Perin J, Herrmann N, Brawman-Mintzer O, Lerner A, Mintzer J, Padala P, Rosenberg P, Shade D, van Dyck C, Porsteinsson A. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial. American Journal Of Geriatric Psychiatry 2023, 31: s100-s101. DOI: 10.1016/j.jagp.2022.12.146.Peer-Reviewed Original ResearchDigit Span BackwardMini-Mental Status ExaminationSelective attentionGlobal cognitionApathy scoresGreater cognitive declineExecutive functionDigit spanCognitive testsCognitionMethylphenidate groupApathy symptomsCognitive declineSignificant apathyMethylphenidateCognitive impairmentStatus ExaminationApathy subscaleMemoryChange scoresApathyDisease dementiaAlzheimer's disease dementiaParticipantsAttention